medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2007, Number 5

<< Back Next >>

Acta Ortop Mex 2007; 21 (5)

Etofenamate and the analgesic effect in the management of acute pain from spine in the emergency room

Acosta PJL, Navarrete MS, Quevedo RE

Language: Spanish
References: 13
Page: 253-255
PDF size: 125.39 Kb.


ABSTRACT

Objective: To demonstrate that the application of etofenamate is effective in management of acute pain. Material and methods: We conducted a prospective, longitudinal, 6 months trial, which included 22 women and 18 men with intense acute low back pain of mechanical or postural aetiology, patients who had pain of traumatic origin and needed radiographic studies by orthopaedic surgeon were excluded; the study subjects were treated with 1 g etofenamate intramuscularly and the analgesic effect was assessed by visual analog scale every 5 minutes for 30 minutes. Results: Marked improvement in pain at 25 minutes in 35 subjects (87.5%). Pain did not improve in 5 subjects (four men, one woman, 12.5%) at 30 minutes. There were no adverse reactions to medication. Discussion: The single dose of 1 g etofenamate is effective in the management of acute pain. Its use prevented 35 admissions with a cost savings of $ 70,000 pesos. Applying etofenamate caused satisfaction of the beneficiaries and emergency personnel, this drug could be an alternative treatment in medical services and first-level emergency.


REFERENCES

  1. Iñárritu A, Bravo P. Lumbalgias. PAC MG1 Programa de actualización continua para Médicos Generales 1999; 4: 25-8.

  2. Margo K. Diagnóstico, tratamiento y pronóstico de los pacientes con dolor de espalda inferior. Am Fam Phys 1995; 2: 127-37.

  3. Dell HD, Beckemann B, Seitz J. The advantages of oil based intramuscular preparations of NSAIDS. Therapiewoche 1991; 41(43): 2798-803.

  4. Fromme K, Kullich W, Klein G. Parenteral use of etofenamate in lumbar syndromes. Therapiewoche 1989; 4(6): 549-51.

  5. Mielkhe K. Injection treatment of acute lumbar syndrome, comparation of etofenamate to diclofenac. Therapiewoche 1990; 40(7): 462-5.

  6. Pelster B. Etofenamate in oily solution new facilities for treatment of severe inflammation pain. Br J Rheumatol 1992; 31 (Suppl 2): 157.

  7. Pelster B. Treatment of rheumatic diseases with etofenamate IM an injectable depot NSAID. Rheumatol Eur 1996; 25 (Suppl 1): 128.

  8. Gniazdowka, Beata R, Franziska P, Pizybilla B. Delayed contact hipersensivity to non-steroidal anti-inflammatory drugs. Contact Dermatitis 1999; 40(2): 63-5.

  9. Montoro J, Rodriguez S, Livana J, et al. Photoallergic contact dermatitis due to flufenamic acid and etofenamate. Contact Dermatitis 1997; 37(3): 139-40.

  10. Unsal A, Cimentepe E, Buzok WA, et al. Comparative study of etofenamate and fentanyl for outpatient extracorporeal. Shockwave Lithotripsy 2001; 35(6): 502-4.

  11. Robert AL, Frank KA, Soberman RJ. Leukotrienes and other products of the lipoxygenase pathway. N Engl J Med 1990; 323(10): 645-55.

  12. Kankaanranta H, Luomala M, Kosonen O. Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. Br J Pharmacol 1996; 119: 487-94.

  13. Opara R, Robbins DL, Ziboh VA. Agonist inhibit antiphospholipid/beta2-glicoprotein 1 induced synthesis of human platelet thromboxane A2 in vitro. Journal of Rheumatol 2003; 30(1): 55-9.




2020     |     www.medigraphic.com